These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 31727111)

  • 1. Systemic bevacizumab for high-output cardiac failure in hereditary hemorrhagic telangiectasia: an international survey of HHT centers.
    Al-Samkari H; Albitar HA; Olitsky SE; Clancy MS; Iyer VN
    Orphanet J Rare Dis; 2019 Nov; 14(1):256. PubMed ID: 31727111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An international survey to evaluate systemic bevacizumab for chronic bleeding in hereditary haemorrhagic telangiectasia.
    Al-Samkari H; Albitar HA; Olitsky SE; Clancy MS; Iyer VN
    Haemophilia; 2020 Nov; 26(6):1038-1045. PubMed ID: 32432841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous Bevacizumab in Hereditary Hemorrhagic Telangiectasia-Related Bleeding and High-Output Cardiac Failure: Significant Inter-Individual Variability in the Need for Maintenance Therapy.
    Albitar HAH; Almodallal Y; Gallo De Moraes A; O'Brien E; Choby GW; Pruthi RK; Stokken JK; Kamath PS; Cajigas HR; DuBrock HM; Krowka MJ; Iyer VN
    Mayo Clin Proc; 2020 Aug; 95(8):1604-1612. PubMed ID: 32753135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High output cardiac failure in 3 patients with hereditary hemorrhagic telangiectasia and hepatic vascular malformations, evaluation of treatment.
    Olsen LB; Kjeldsen AD; Poulsen MK; Kjeldsen J; Fialla AD
    Orphanet J Rare Dis; 2020 Nov; 15(1):334. PubMed ID: 33243256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output.
    Dupuis-Girod S; Ginon I; Saurin JC; Marion D; Guillot E; Decullier E; Roux A; Carette MF; Gilbert-Dussardier B; Hatron PY; Lacombe P; Lorcerie B; Rivière S; Corre R; Giraud S; Bailly S; Paintaud G; Ternant D; Valette PJ; Plauchu H; Faure F
    JAMA; 2012 Mar; 307(9):948-55. PubMed ID: 22396517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Bevacizumab: a new success in hereditary hemorrhagic telangiectasia].
    Bennesser Alaoui H; Lehraiki M; Hamaz S; El Attar N; Fakhreddine N; Serraj K
    Rev Med Interne; 2015 Sep; 36(9):623-5. PubMed ID: 25595875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia.
    Buscarini E; Botella LM; Geisthoff U; Kjeldsen AD; Mager HJ; Pagella F; Suppressa P; Zarrabeitia R; Dupuis-Girod S; Shovlin CL;
    Orphanet J Rare Dis; 2019 Feb; 14(1):28. PubMed ID: 30717761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia.
    Al-Samkari H; Kritharis A; Rodriguez-Lopez JM; Kuter DJ
    J Intern Med; 2019 Feb; 285(2):223-231. PubMed ID: 30191646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intra-venous bevacizumab in hereditary hemorrhagic telangiectasia (HHT): A retrospective study of 46 patients.
    Guilhem A; Fargeton AE; Simon AC; Duffau P; Harle JR; Lavigne C; Carette MF; Bletry O; Kaminsky P; Leguy V; Lerolle N; Roux D; Lambert M; Chinet T; Bonnet D; Dupuis-Girod S; Rivière S
    PLoS One; 2017; 12(11):e0188943. PubMed ID: 29190827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study.
    Al-Samkari H; Kasthuri RS; Parambil JG; Albitar HA; Almodallal YA; Vázquez C; Serra MM; Dupuis-Girod S; Wilsen CB; McWilliams JP; Fountain EH; Gossage JR; Weiss CR; Latif MA; Issachar A; Mei-Zahav M; Meek ME; Conrad M; Rodriguez-Lopez J; Kuter DJ; Iyer VN
    Haematologica; 2021 Aug; 106(8):2161-2169. PubMed ID: 32675221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab for treating Hereditary Hemorrhagic Telangiectasia patients with severe hepatic involvement or refractory anemia.
    Vázquez C; Gonzalez ML; Ferraris A; Bandi JC; Serra MM
    PLoS One; 2020; 15(2):e0228486. PubMed ID: 32032395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Topical Intranasal Therapy on Epistaxis Frequency in Patients With Hereditary Hemorrhagic Telangiectasia: A Randomized Clinical Trial.
    Whitehead KJ; Sautter NB; McWilliams JP; Chakinala MM; Merlo CA; Johnson MH; James M; Everett EM; Clancy MS; Faughnan ME; Oh SP; Olitsky SE; Pyeritz RE; Gossage JR
    JAMA; 2016 Sep; 316(9):943-51. PubMed ID: 27599329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose - response relationship of bevacizumab in hereditary hemorrhagic telangiectasia.
    Azzopardi N; Dupuis-Girod S; Ternant D; Fargeton AE; Ginon I; Faure F; Decullier E; Roux A; Carette MF; Gilbert-Dussardier B; Hatron PY; Lacombe P; Leguy-Seguin V; Rivière S; Corre R; Bailly S; Paintaud G
    MAbs; 2015; 7(3):630-7. PubMed ID: 25751241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hereditary hemorrhagic telangiectasia (OslerWeberRendu syndrome) - Part II. Pharmacological therapy and international guidelines for the therapy 2020.
    Adam Z; Brančiková D; Romanová G; Pour L; Krejčí M; König J; Nebeský T; Adamová Z; Štork M; Krejčí M; Ševčíková S; Eid M; Sandecká V; Král Z
    Vnitr Lek; 2021; 67(7):419-424. PubMed ID: 35459360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful therapy with bevacizumab in a case of hereditary hemorrhagic telangiectasia.
    Kochanowski J; Sobieszczańska M; Tubek S; Żurek M; Pawełczak J
    Hum Vaccin Immunother; 2015; 11(3):680-1. PubMed ID: 25839219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic therapy with bevacizumab in patients with hereditary hemorrhagic telangiectasia (HHT).
    Chavan A; Schumann-Binarsch S; Luthe L; Nickau B; Elsässer A; Kühnel T; Geisthoff U; Köhne H
    Vasa; 2013 Mar; 42(2):106-10. PubMed ID: 23485837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab to Treat Cholangiopathy in Hereditary Hemorrhagic Telangiectasia: Be Cautious: A Case Report.
    Maestraggi Q; Bouattour M; Toquet S; Jaussaud R; Kianmanesh R; Durand F; Servettaz A
    Medicine (Baltimore); 2015 Nov; 94(46):e1966. PubMed ID: 26579805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranasal submucosal bevacizumab for epistaxis in hereditary hemorrhagic telangiectasia: a double-blind, randomized, placebo-controlled trial.
    Riss D; Burian M; Wolf A; Kranebitter V; Kaider A; Arnoldner C
    Head Neck; 2015 Jun; 37(6):783-7. PubMed ID: 24595923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hereditary haemorrhagic telangiectasia: to transplant or not to transplant - is there a right time for liver transplantation?
    Muller YD; Oppliger R; Breguet R; Meyer P; Rubbia-Brandt L; Petignat PA; Harr T; Dayer E; Seebach JD
    Liver Int; 2016 Dec; 36(12):1735-1740. PubMed ID: 27864873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab as a treatment for hereditary hemorrhagic telangiectasia in children: a case report.
    Ospina FE; Echeverri A; Posso-Osorio I; Jaimes L; Gutierrez J; Tobón GJ
    Colomb Med (Cali); 2017 Jun; 48(2):88-93. PubMed ID: 29021642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.